Congress trades
Emergent BioSolutions Inc. (EBS)
About Emergent BioSolutions Inc.
from the company's filings and listing- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Chief executive
- Joseph C. Papa Jr.
- Employees
- 900
- Listed since
- Nov 15, 2006
- Market value
- $293.1M
- Price to earnings
- -
- Earnings per share
- -$3.43
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 4, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | $0.60 | -$0.09 | $234.3M | $177.5M | EPS beatRevenue beat |
| Q1 FY2026reported Apr 30, 2026 | $0.21 | -$0.25 | $156.1M | $145.0M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 26, 2026 | -$0.43 | $0.11 | $148.7M | $217.5M | EPS missRevenue miss |
| Q3 FY2025reported Oct 29, 2025 | $1.06 | -$0.12 | $231.1M | $217.5M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 6, 2025 | $0.16 | -$0.26 | $140.9M | $203.7M | EPS beatRevenue miss |
| Q1 FY2025reported May 7, 2025 | $0.71 | $0.49 | $222.2M | $219.0M | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Mar 20, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Joseph PapaPresident, Chief Executive Officer and Director | $1.0M | $1.6M | $2.6M | $5.3M |
| Richard LindahlExecutive Vice President, Chief Financial Officer | $662K | $852K | $1.2M | $2.7M |
| Coleen GlessnerExecutive Vice President, Quality and Ethics and Compl | $624K | $363K | $678K | $1.7M |
| Simon LowryChief Medical Officer and Head of Research and Develop | $545K | $363K | $564K | $1.5M |
| Paul WilliamsSenior Vice President, Products Business | $495K | $363K | $534K | $1.4M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $39.5M | 4,716,599 | +8.6% | 9.14% |
| Dimensional Fund Advisors LP | $25.8M | 3,076,646 | +11.6% | 5.96% |
| State Street Corp | $24.6M | 2,929,238 | +2.8% | 5.68% |
| American Century Companies Inc | $23.2M | 2,770,448 | +14.2% | 5.37% |
| Vanguard Capital Management LLC | $18.4M | 2,198,839 | -2.6% | 4.26% |
| LSV Asset Management | $14.2M | 1,695,851 | +89.1% | 3.29% |
| Acadian Asset Management LLC | $11.3M | 1,344,323 | -2.7% | 2.61% |
| Geode Capital Management, LLC | $11.2M | 1,337,243 | +5.1% | 2.59% |
| Sixth Street Partners Management Company, L.P. | $10.1M | 1,200,791 | +100.0% | 2.33% |
| Charles Schwab Investment Management Inc | $10.1M | 1,200,791 | -20.3% | 2.33% |
| Oak Hill Advisors LP | $9.3M | 1,113,338 | 0.0% | 2.16% |
| Millennium Management LLC | $9.0M | 1,072,185 | +101.5% | 2.08% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in EBS
13 disclosures of 13 on record · median 24d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Steve Cohen | Stock | Sale | $1,001 - $15,000 | -33.7%S&P +25.5% · vs S&P 500 -59.2% | Dec 11, 2024 | Jan 10, 2025 | 30d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -82.8%S&P +62.7% · vs S&P 500 -145.6% | Nov 5, 2021 | Dec 13, 2021 | 38d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -88.7%S&P +70.5% · vs S&P 500 -159.2% | Oct 18, 2021 | Nov 15, 2021 | 28d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -90.1%S&P +70.2% · vs S&P 500 -160.2% | Sep 15, 2021 | Oct 13, 2021 | 28d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -93.9%S&P +96.8% · vs S&P 500 -190.7% | Feb 23, 2021 | Mar 10, 2021 | 15d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -92.8%S&P +110.0% · vs S&P 500 -202.8% | Nov 24, 2020 | Dec 15, 2020 | 21d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -94.1%S&P +135.5% · vs S&P 500 -229.6% | Jul 30, 2020 | Aug 19, 2020 | 20d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -92.8%S&P +147.3% · vs S&P 500 -240.1% | Jun 30, 2020 | Jul 17, 2020 | 17d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -92.1%S&P +146.0% · vs S&P 500 -238.0% | Jun 19, 2020 | Jul 17, 2020 | 28d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -92.0%S&P +148.4% · vs S&P 500 -240.4% | Jun 15, 2020 | Jul 9, 2020 | 24d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -92.4%S&P +152.9% · vs S&P 500 -245.4% | Jun 26, 2020 | Jul 9, 2020 | 13d |
| Steve Cohen | Stock | Sale | $1,001 - $15,000 | -90.1%S&P +191.7% · vs S&P 500 -281.8% | Mar 26, 2020 | Apr 22, 2020 | 27d |
| Steve Cohen | Stock | Sale | $15,001 - $50,000 | -86.6%S&P +160.8% · vs S&P 500 -247.4% | Aug 29, 2019 | Sep 12, 2019 | 14d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded EBS?
Steve Cohen, Josh Gottheimer, Gilbert Ray Cisneros, Jr. disclosed EBS transactions in the filings shown here.
How quickly are EBS trades disclosed?
Congressional disclosures took a median of 24 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.